Mild method for the synthesis of 1H-indazoles through oxime-phosphonium ion intermediate
摘要:
The synthesis of 1H-indazoles from o-aminobenzoximes is achieved via N-N bond formation using triphenylphosphine, 12, and imidazole. Selective formation of oxime-phosphonium ion intermediate in the presence of the amino group is the driving force for this reaction. The nucleophilicity of the arylamino group and electrophilicity toward the N-O bond of oxime also control the reaction. The reaction proceeds at a faster rate with good to excellent yield under this mild reaction condition and is amenable to scale-up. (C) 2014 Elsevier Ltd. All rights reserved.
A Practical, Metal-Free Synthesis of 1<i>H</i>-Indazoles
作者:Carla M. Counceller、Chad C. Eichman、Brenda C. Wray、James P. Stambuli
DOI:10.1021/ol800053f
日期:2008.3.1
The synthesis of 1H-indazoles is achieved from o-aminobenzoximes by the selective activation of the oxime in the presence of the amino group. The reaction occurs with a variety of substituted o-aminobenzoximes using a slight excess of methanesulfonyl chloride and triethylamine at 0-23 degrees C and is amenable to scale-up. The synthesis of 1H-indazoles under these conditions is extremely mild compared
A method is provided for synthesizing 1H-indazole compounds in which aromatic carbonyl compounds are reacted with a nitrogen source to form oximes which are then converted to 1H-indazoles.
The invention relates to substituted phenylquinazoline derivatives. It concerns the compounds of formula I
wherein the substituents have various significances.
They may be obtained by a process comprising dehydration, ring closure and/or alkylation, and optional recovery in racemic or optically active, in free base or acid addition salt form.
They possess pharmacological activity, in particular,they raise the blood serum high density lipoprotein level and are thus indicated for use in the treatment of atherosclerosis.
This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.